Publications by authors named "Israel Lowy"

Claim this Profile
C
Cemiplimab in Japanese patients with advanced non-small cell lung cancer.
Yuki Sato, Yoko Tani, Hidenobu Ishii, Seigo Katakura, Masahide Oki, Israel Lowy

Jpn J Clin Oncol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Interchangeability of PD-L1 Immunohistochemistry Assays in First-Line Non-Small Cell Lung Cancer Management With Cemiplimab.
Javier Perez, Keith M Kerr, Brian Baker, Fang Fang, Jason Li, Israel Lowy

JCO Precis Oncol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Adjuvant Cemiplimab or Placebo in High-Risk Cutaneous Squamous-Cell Carcinoma.
Danny Rischin, Sandro Porceddu, Fiona Day, Daniel P Brungs, Hayden Christie, Israel Lowy

N Engl J Med· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab Monotherapy for First-Line Treatment of Patients with Advanced NSCLC With PD-L1 Expression of 50% or Higher: Five-Year Outcomes of EMPOWER-Lung 1.
Saadettin Kilickap, Ana Baramidze, Ahmet Sezer, Mustafa Özgüroğlu, Mahmut Gumus, Israel Lowy

J Thorac Oncol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab plus peltopepimut-S vaccine in recurrent cervical cancer: A phase 2 clinical trial.
Domenica Lorusso, Ana Oaknin, Giuliano S Borges, Fernanda Damian, Nelleke Ottevanger, Israel Lowy

Gynecol Oncol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab in recurrent cervical cancer: Final analysis of overall survival in the phase III EMPOWER-Cervical 1/GOG-3016/ENGOT-cx9 trial.
Ana Oaknin, Bradley J Monk, Andreia Cristina de Melo, Hee Seung Kim, Yong Man Kim, Israel Lowy

Eur J Cancer· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of groups 1, 2, and 3, and primary analysis of fixed-dose treatment group 6.
Brett G M Hughes, Alexander Guminski, Samantha Bowyer, Michael R Migden, Chrysalyne D Schmults, Israel Lowy

J Am Acad Dermatol· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-Human Dose-Escalation Study of Fianlimab, an Antilymphocyte Activation Gene-3 Antibody, with Cemiplimab in Patients with Advanced Malignancies.
Nehal J Lakhani, Kyriakos P Papadopoulos, Melissa Lynne Johnson, Haeseong Park, Ding Wang, Israel Lowy

Clin Cancer Res· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.
Kosei Hasegawa, Shunji Takahashi, Kimio Ushijima, Masao Okadome, Kan Yonemori, Israel Lowy

Cancer Med· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Fianlimab, a Human Lymphocyte Activation Gene-3 (LAG-3) Monoclonal Antibody, in Combination With Cemiplimab in Advanced Melanoma.
Omid Hamid, Karl D Lewis, Amy Weise, Meredith McKean, Kyriakos P Papadopoulos, Israel Lowy

J Clin Oncol· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High response rate with extended dosing of cemiplimab in advanced cutaneous squamous cell carcinoma.
Danny Rischin, Brett G M Hughes, Nicole Basset-Séguin, Dirk Schadendorf, Samantha Bowyer, Israel Lowy

J Immunother Cancer· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-up.
Alexander J Stratigos, Aleksandar Sekulic, Ketty Peris, Oliver Bechter, Sorilla Prey, Israel Lowy

J Am Acad Dermatol· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.
Neil D Gross, David M Miller, Nikhil I Khushalani, Vasu Divi, Emily S Ruiz, Israel Lowy

Lancet Oncol· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-PD-1 immunotherapy with androgen deprivation therapy induces robust immune infiltration in metastatic castration-sensitive prostate cancer.
Jessica E Hawley, Aleksandar Z Obradovic, Matthew C Dallos, Emerson A Lim, Karie Runcie, Israel Lowy

Cancer Cell· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial.
Mustafa Özgüroğlu, Saadettin Kilickap, Ahmet Sezer, Mahmut Gümüş, Igor Bondarenko, Israel Lowy

Lancet Oncol· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Response to Letter to the Editor.
Tamta Makharadze, Miranda Gogishvili, Ana Baramidze, Siyu Li, Yuntong Li, Israel Lowy

J Thorac Oncol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial.
Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze, Ana Baramidze, Davit Giorgadze, Israel Lowy

J Thorac Oncol· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates.
Julie R Brahmer, Charles G Drake, Ira Wollner, John D Powderly, Joel Picus, Israel Lowy

J Clin Oncol· February 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer cell-derived type I interferons instruct tumor monocyte polarization.
Dylan Kwart, Jing He, Subhashini Srivatsan, Clarissa Lett, Jacquelynn Golubov, Israel Lowy

Cell Rep· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial.
Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze, Davit Giorgadze, Mikhail Dvorkin, Israel Lowy

Nat Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD22-targeted CD28 bispecific antibody enhances antitumor efficacy of odronextamab in refractory diffuse large B cell lymphoma models.
Joyce Wei, Welby Montalvo-Ortiz, Lola Yu, Amanda Krasco, Kara Olson, Israel Lowy

Sci Transl Med· November 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
EMPOWER CERVICAL-1: Effects of cemiplimab versus chemotherapy on patient-reported quality of life, functioning and symptoms among women with recurrent cervical cancer.
Ana Oaknin, Bradley J Monk, Ignace Vergote, Andreia Cristina de Melo, Yong-Man Kim, Israel Lowy

Eur J Cancer· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
Neil D Gross, David M Miller, Nikhil I Khushalani, Vasu Divi, Emily S Ruiz, Israel Lowy

N Engl J Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immunotherapy for resectable hepatocellular carcinoma - Authors' reply.
Thomas U Marron, Myron E Schwartz, Elizabeth Miller, Pradeep Thanigaimani, Israel Lowy

Lancet Gastroenterol Hepatol· June 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.
Rajat Bannerji, Jon E Arnason, Ranjana H Advani, Jennifer R Brown, John N Allan, Israel Lowy

Lancet Haematol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis